How would you sequence 177LU-PSMA-617 with current therapies for men with mCRPC?
Community PollStarted
Assuming approval of 177-Lu-PSMA-116, what would you use for a patient with bone-only mCRPC after progression on 1 prior ARSI + docetaxel?
54 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Johns Hopkins University
Answered on
I would like to congratulate the VISION study investigators and Dr. @Dr. First Last for the outstanding presentation and good news. The study was designed to use a hybrid control (best "standard of care"-SOC) and as such, it met its endpoints (OS, rPFS, etc). Secondary endpoints also significantly f...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Vanderbilt-Ingram Cancer Center
Answered on
We discuss these data and where this agent fits into the mCRPC landscape on a recent Uromigos podcast: https://anchor.fm/the-uromigos/episodes/Episode-113-Radionucleotides-in-prostate-cancer-e130uuq.
Join for free or sign in to see the full answer